论文部分内容阅读
采用多克隆抗体Ｎ２１对２１７例乳腺良、恶性肿瘤作了癌基因Ｃ－ｅｒｂＢ－２表达产物的免疫组化研究。结果发现，１６７例乳腺癌中６６例（３９．５％）Ｃ－ｅｒｂＢ－２有过度表达，全部为浸润性导管癌。５０例乳腺良性病变Ｃ－ｅｒｂＢ－２全部为阴性。Ｃ－ｅｒｂＢ－２过度表达与组织学细胞分级、淋巴结转移度、死亡率、复发率呈正相关系，统计学检验差异高度显著。且用Ｃ－ｅｒｂＢ－２表达情况观测乳腺癌预后优于用淋巴结转移来观测预后，但两者联合应用观测乳腺病预后更为全面可靠。
The polyclonal antibody N21 was used to study the expression of C-erbB-2 in 217 breast benign and malignant tumors. It was found that 66 (39.5%) of the 167 cases of breast cancer had overexpression of C-erbB-2, all of which were invasive ductal carcinomas. All 50 cases of benign breast lesions were negative for C-erbB-2. C-erbB-2 overexpression was positively correlated with histological grade, lymph node metastasis, mortality, and recurrence rate, and the statistically significant differences were statistically significant. Moreover, the prognosis of breast cancer was better observed by C-erbB-2 expression than that by lymph node metastasis, but the combination of the two methods was more complete and reliable.